Immunocord
Graft Engineering of Cord Blood for Enhanced Adoptive Immunotherapy Against Solid Tumors
Health Tech & Life Sciences
Non Active, May 2018
Company Overview
Snapshot
Founded in February 2016 by Amnon Pelz, Immunocord operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its core technology.
Business overview
Immunocord is a Health Tech & Life Sciences company specializing in medical technologies within the Digital Health and Medical Technologies sector. The company has developed a solution for graft engineering of cord blood, aiming to enhance adoptive immunotherapy against solid tumors. Its core technology addresses critical needs in oncology and immunology, serving the healthcare market, particularly providers, with a B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is Immunocord's primary focus?
- Immunocord focuses on graft engineering of cord blood for enhanced adoptive immunotherapy against solid tumors, operating within the Health Tech & Life Sciences sector.
- When was Immunocord founded?
- Immunocord was founded in February 2016.
- Who is the founder of Immunocord?
- Amnon Pelz is the Founder & CEO of Immunocord.
- What is Immunocord's current funding stage?
- Immunocord is currently in a Pre-Funding stage, indicating it has not yet raised external capital.
- What markets does Immunocord target?
- Immunocord targets the healthcare market, specifically providers, with a B2B business model, focusing on applications in oncology and immunology.